Taming fatty liver: can taurine combat metabolic dysfunction in MASLD?
Abstract
Metabolic dysfunction associated with steatotic liver disease (MASLD) is the most prevalent chronic liver disease globally, significantly impacting human health and imposing substantial socioeconomic burdens. Characterized by excessive lipid accumulation in the liver, MASLD can progress to non-alcoholic steatohepatitis (NASH), fibrosis, and hepatocellular carcinoma (HCC). Despite extensive research, the molecular mechanisms underlying MASLD remain incompletely understood, and no effective pharmacological treatments have been approved. This review explores the potential mechanisms of MASLD pathogenesis, early diagnostic approaches, and the promising role of taurine in mitigating MASLD progression via the gut-liver axis. As research advances, taurine may offer a novel therapeutic avenue, presenting new possibilities for effective clinical interventions in MASLD management.
Read the paper
Related studies
- Metabolic Syndrome: Updates on Pathophysiology and Management in 2021
- Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases
- Antioxidants, inflammation and cardiovascular disease
- Application of Metabolomics in Alzheimer’s Disease
- Nutritional Importance of Carotenoids and Their Effect on Liver Health: A Review
- Nutritional essentiality of sulfur in health and disease
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.